Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's Inflation Reduction Act (IRA) but will look at refining the programme.
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim ...
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
Mads Petersen, owner of Greenland-based startup Arctic Unmanned, sat in a car to keep warm while he tested a small drone at ...
but which could raise considerably more – would help the company accelerate the clinical development of its pipeline of obesity candidates as it chases down market leaders Novo Nordisk and Eli ...
In a healthcare market brimming with potential, DarioHealth Corp. * is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it ...